Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TPTX, IWM, AVIR, FMTX, BBIO, and represent 28.41% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 10 stocks: GLUE (+$70M), ARKG (+$69M), ARKK (+$65M), BMEA (+$48M), AMAM (+$47M), AVTE (+$45M), VERV (+$41M), RAIN (+$40M), CNTA (+$31M), RVMD (+$26M).
- Started 15 new stock positions in AMAM, Catabasis Pharmaceuticals Ord, ARKG, GLUE, VECT, VERV, GHRS, ARKK, BMEA, ELEV. RAIN, CNTA, TALS, AVTE, GRPH.
- Reduced shares in these 10 stocks: , IWM (-$229M), , CCCC (-$81M), APLS (-$64M), NVAX (-$45M), , RETA (-$33M), OMER (-$31M), NTLA (-$24M).
- Sold out of its positions in ALBO, ALLK, ARNA, ARGX, AXSM, BNTX, CCXI, CGEM, FATE, FHTX.
- Cormorant Asset Management was a net seller of stock by $-1.1B.
- Cormorant Asset Management has $2.9B in assets under management (AUM), dropping by -34.42%.
- Central Index Key (CIK): 0001583977
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cormorant Asset Management
Companies in the Cormorant Asset Management portfolio as of the June 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Turning Point Therapeutics I (TPTX) | 8.0 | $237M | +10% | 3.0M | 78.02 | |
| Ishares Tr Russell 2000 Etf Put Option (IWM) | 7.8 | $229M | -50% | 1.0M | 229.37 | |
| Atea Pharmaceuticals (AVIR) | 4.7 | $138M | 6.4M | 21.48 | ||
| Forma Therapeutics Hldgs SHS (FMTX) | 4.0 | $118M | 4.7M | 24.89 | ||
| Bridgebio Pharma (BBIO) | 3.9 | $115M | -13% | 1.9M | 60.96 | |
| Design Therapeutics (DSGN) | 3.6 | $106M | +5% | 5.4M | 19.57 | |
| Revolution Medicines (RVMD) | 3.6 | $106M | +32% | 3.3M | 31.74 | |
| Olema Pharmaceuticals (OLMA) | 2.9 | $86M | -3% | 3.1M | 27.98 | |
| Bioatla (BCAB) | 2.8 | $83M | -10% | 2.0M | 42.38 | |
| Monte Rosa Therapeutics (GLUE) | 2.4 | $70M | NEW | 3.2M | 21.78 | |
| Ark Etf Tr Genomic Rev Etf Put Option (ARKG) | 2.4 | $69M | NEW | 750k | 92.50 | |
| Edgewise Therapeutics (EWTX) | 2.3 | $67M | +34% | 3.1M | 21.18 | |
| Ark Etf Tr Innovation Etf Put Option (ARKK) | 2.2 | $65M | NEW | 500k | 130.78 | |
| Avidity Biosciences Ord (RNA) | 1.9 | $55M | -9% | 2.2M | 24.71 | |
| Apellis Pharmaceuticals (APLS) | 1.8 | $54M | -54% | 850k | 63.20 | |
| Alx Oncology Hldgs (ALXO) | 1.7 | $49M | 890k | 54.68 | ||
| Biomea Fusion (BMEA) | 1.6 | $48M | NEW | 3.2M | 15.27 | |
| Ambrx Biopharma Sponsored Ads (AMAM) | 1.6 | $47M | NEW | 2.5M | 18.92 | |
| Zymeworks (ZYME) | 1.6 | $46M | -33% | 1.3M | 34.69 | |
| Aerovate Therapeutics (AVTE) | 1.5 | $45M | NEW | 2.0M | 21.97 | |
| Prometheus Biosciences (RXDX) | 1.5 | $45M | -11% | 1.8M | 24.07 | |
| Tarsus Pharmaceuticals (TARS) | 1.5 | $44M | -11% | 1.5M | 28.98 | |
| Stoke Therapeutics (STOK) | 1.5 | $43M | -11% | 1.3M | 33.66 | |
| Rocket Pharmaceuticals (RCKT) | 1.5 | $43M | -29% | 969k | 44.29 | |
| Verve Therapeutics (VERV) | 1.4 | $41M | NEW | 709k | 57.24 | |
| Rain Therapeutics (RAIN) | 1.3 | $40M | NEW | 2.6M | 15.13 | |
| Aclaris Therapeutics (ACRS) | 1.2 | $35M | 2.0M | 17.56 | ||
| Omeros Corporation (OMER) | 1.1 | $33M | -48% | 2.2M | 14.84 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.1 | $31M | NEW | 1.4M | 21.76 | |
| Mirati Therapeutics (MRTX) | 1.0 | $28M | -36% | 175k | 161.53 | |
| Y Mabs Therapeutics (YMAB) | 0.9 | $27M | -34% | 800k | 33.80 | |
| Agenus Com New (AGEN) | 0.9 | $26M | -37% | 4.8M | 5.49 | |
| Elevation Oncology (ELEV) | 0.9 | $26M | NEW | 2.0M | 12.89 | |
| Vectivbio Hldg Ord Shs (VECT) | 0.9 | $26M | NEW | 2.2M | 11.47 | |
| Twist Bioscience Corp (TWST) | 0.8 | $25M | 185k | 133.25 | ||
| Reata Pharmaceuticals Cl A (RETA) | 0.8 | $24M | -57% | 168k | 141.53 | |
| Acceleron Pharma (XLRN) | 0.7 | $22M | -36% | 175k | 125.49 | |
| 908 Devices (MASS) | 0.7 | $21M | 545k | 38.75 | ||
| Blueprint Medicines (BPMC) | 0.7 | $21M | -3% | 238k | 87.96 | |
| Longboard Pharmaceuticals In (LBPH) | 0.7 | $21M | 2.3M | 8.99 | ||
| Igm Biosciences (IGMS) | 0.7 | $21M | -49% | 250k | 83.20 | |
| Axonics Modulation Technolog (AXNX) | 0.7 | $20M | -53% | 322k | 63.41 | |
| Praxis Precision Medicines I (PRAX) | 0.6 | $19M | -4% | 1.0M | 18.28 | |
| Dermtech Ord ord (DMTK) | 0.6 | $19M | -43% | 450k | 41.57 | |
| Aligos Therapeutics (ALGS) | 0.6 | $19M | -28% | 906k | 20.39 | |
| Talaris Therapeutics (TALS) | 0.6 | $17M | NEW | 1.2M | 14.20 | |
| Akero Therapeutics (AKRO) | 0.5 | $15M | -19% | 600k | 24.81 | |
| Pliant Therapeutics (PLRX) | 0.5 | $14M | -21% | 482k | 29.12 | |
| Cabaletta Bio (CABA) | 0.5 | $14M | -15% | 1.6M | 8.60 | |
| Pharvaris N V (PHVS) | 0.5 | $14M | -13% | 745k | 18.30 | |
| C4 Therapeutics Com Stk (CCCC) | 0.5 | $13M | -85% | 355k | 37.84 | |
| Beam Therapeutics (BEAM) | 0.4 | $13M | -41% | 100k | 128.71 | |
| Connect Biopharma Hldgs Ads (CNTB) | 0.4 | $13M | -35% | 650k | 19.53 | |
| Aptose Biosciences Com New (APTO) | 0.4 | $13M | -4% | 3.8M | 3.32 | |
| Gh Research Ordinary Shares (GHRS) | 0.4 | $13M | NEW | 608k | 20.64 | |
| Myovant Sciences (MYOV) | 0.4 | $12M | -45% | 543k | 22.77 | |
| Repare Therapeutics Ord (RPTX) | 0.4 | $11M | -21% | 364k | 31.18 | |
| Eledon Pharmaceuticals (ELDN) | 0.4 | $11M | 1.4M | 7.91 | ||
| Morphic Hldg (MORF) | 0.4 | $11M | -45% | 190k | 57.39 | |
| Humanigen Com New (HGEN) | 0.4 | $10M | -40% | 600k | 17.38 | |
| Anaptysbio Inc Common (ANAB) | 0.3 | $10M | -40% | 385k | 25.93 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.3 | $9.9M | -25% | 75k | 131.55 | |
| Zai Lab Adr (ZLAB) | 0.3 | $9.5M | -64% | 54k | 176.99 | |
| Inspire Med Sys (INSP) | 0.3 | $9.3M | -43% | 48k | 193.26 | |
| Bctg Acquisition Corp | 0.3 | $9.1M | 800k | 11.37 | ||
| Galecto (GLTO) | 0.3 | $8.9M | -18% | 1.8M | 5.06 | |
| Tcr2 Therapeutics Inc cs (TCRR) | 0.3 | $7.9M | -46% | 480k | 16.41 | |
| Harpoon Therapeutics (HARP) | 0.3 | $7.5M | -5% | 541k | 13.87 | |
| Catabasis Pharmaceuticals In Com New | 0.3 | $7.5M | NEW | 3.6M | 2.11 | |
| Iteos Therapeutics (ITOS) | 0.3 | $7.4M | -3% | 288k | 25.65 | |
| Silverback Therapeutics (SBTX) | 0.3 | $7.4M | -52% | 239k | 30.89 | |
| Uniqure Nv SHS (QURE) | 0.3 | $7.4M | -4% | 240k | 30.80 | |
| Insmed Com Par $.01 (INSM) | 0.2 | $7.1M | -16% | 250k | 28.46 | |
| Female Health (VERU) | 0.2 | $6.5M | -73% | 800k | 8.07 | |
| Miragen Therapeutics (VRDN) | 0.2 | $6.3M | -25% | 343k | 18.29 | |
| Merus N V (MRUS) | 0.2 | $6.0M | -18% | 285k | 21.07 | |
| Graphite Bio (GRPH) | 0.2 | $5.9M | NEW | 203k | 29.19 | |
| Aveo Pharmaceuticals Com New (AVEO) | 0.2 | $5.9M | -40% | 894k | 6.59 | |
| Deciphera Pharmaceuticals (DCPH) | 0.2 | $5.3M | -27% | 144k | 36.61 | |
| Akouos (AKUS) | 0.2 | $5.0M | -21% | 395k | 12.55 | |
| Sorrento Therapeutics Com New (SRNE) | 0.2 | $4.8M | -81% | 500k | 9.69 | |
| Magenta Therapeutics (MGTA) | 0.2 | $4.7M | -20% | 478k | 9.78 | |
| Helix Acquisition Corp Com Cl A (HLXA) | 0.2 | $4.4M | 430k | 10.35 | ||
| Quotient SHS (QTNT) | 0.1 | $4.4M | -19% | 1.2M | 3.64 | |
| Theravance Biopharma (TBPH) | 0.1 | $4.4M | -45% | 300k | 14.52 | |
| Precision Biosciences Ord (DTIL) | 0.1 | $4.3M | 347k | 12.52 | ||
| 5 01 Acquisition Corp Com Cl A (FVAM) | 0.1 | $4.0M | -20% | 400k | 9.97 | |
| Genetron Hldgs Ads (GTH) | 0.1 | $2.7M | -55% | 133k | 20.14 | |
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $2.6M | -7% | 392k | 6.64 | |
| Health Sciences Acq Corp 2 Ord Shs (HSAQ) | 0.1 | $2.4M | -70% | 240k | 10.20 | |
| Eiger Biopharmaceuticals (EIGR) | 0.1 | $2.4M | -28% | 285k | 8.52 | |
| Atreca Cl A Com (BCEL) | 0.1 | $2.3M | -6% | 274k | 8.52 | |
| Tricida (TCDA) | 0.1 | $1.8M | 428k | 4.32 | ||
| Gossamer Bio (GOSS) | 0.1 | $1.6M | -76% | 198k | 8.12 | |
| Springworks Therapeutics (SWTX) | 0.0 | $1.2M | -88% | 15k | 82.40 | |
| Orchard Therapeutics Ads (ORTX) | 0.0 | $1.1M | 257k | 4.39 | ||
| X4 Pharmaceuticals (XFOR) | 0.0 | $676k | 104k | 6.50 | ||
| Cardiff Oncology (CRDF) | 0.0 | $637k | -36% | 96k | 6.65 | |
| Minerva Neurosciences (NERV) | 0.0 | $570k | +22% | 246k | 2.32 | |
| Imv (IMV) | 0.0 | $507k | 234k | 2.16 | ||
| Cerevel Therapeutics Hldng I *w Exp 06/09/202 (CEREW) | 0.0 | $278k | -85% | 19k | 14.39 | |
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $217k | 83k | 2.60 | ||
| Outlook Therapeutics *w Exp 02/18/202 (OTLKW) | 0.0 | $130k | 417k | 0.31 |
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2021 Q2 filed Aug. 16, 2021
- Cormorant Asset Management 2021 Q1 filed May 17, 2021
- Cormorant Asset Management 2020 Q4 filed Feb. 16, 2021
- Cormorant Asset Management 2020 Q3 filed Nov. 16, 2020
- Cormorant Asset Management 2020 Q2 filed Aug. 14, 2020
- Cormorant Asset Management 2020 Q1 filed May 15, 2020
- Cormorant Asset Management 2019 Q4 filed Feb. 14, 2020
- Cormorant Asset Management 2019 Q3 filed Nov. 14, 2019
- Cormorant Asset Management 2019 Q2 filed Aug. 14, 2019
- Cormorant Asset Management 2019 Q1 filed May 15, 2019
- Cormorant Asset Management 2018 Q4 filed Feb. 14, 2019
- Cormorant Asset Management 2018 Q3 filed Nov. 14, 2018
- Cormorant Asset Management 2018 Q2 filed Aug. 14, 2018
- Cormorant Asset Management 2018 Q1 filed May 15, 2018
- Cormorant Asset Management 2017 Q4 filed Feb. 14, 2018
- Cormorant Asset Management 2017 Q3 filed Nov. 14, 2017